

Peptonic Medical: Uppsala District Court approves extension of corporate reconstruction

Peptonic Medical AB (publ) ("Peptonic" or the "Company") announces that the Uppsala District Court today, on 19 September 2025, has approved the Company's request to extend its ongoing corporate reconstruction by three months, until 16 December 2025.

The purpose of the extension is to finalize the reconstruction plan and apply for a plan hearing in accordance with the Swedish Corporate Reconstruction Act. The Company intends to submit the reconstruction plan to relevant parties and apply for a plan hearing in the coming weeks, no later than the end of September 2025.

For further information, please contact:

Anna Linton, CEO, Peptonic Medical AB

Email: anna.linton@peptonicmedical.se

Phone: +46 70-244 92 07

About Peptonic Medical AB

PEPTONIC medical AB (publ) is a pioneering Swedish medtech company specializing in the development and sale of clinically proven self-care products for women's intimate health. Through its brands VagiVital and Vernivia, the Company offers a broad over-the-counter portfolio of effective and gentle products designed to help women understand, treat, and prevent common medical conditions in the intimate area. Peptonic's growth strategy centers on geographic expansion, particularly in the U.S. and Europe, while continually enhancing its product portfolio through in-house development and strategic acquisitions.

The Company is headquartered in Stockholm, Sweden, and operates the subsidiaries, Peptonic Medical Inc. and Common Sense Marketing Inc., in the U.S. Peptonic Medical was founded in 2009 and has been listed on the Spotlight Stock Market since 2014.